Teneligliptin

Teneligliptin should be used with caution with drugs that can enhance the blood glucose lowering effect (e.g., β-blockers, MAO inhibitors, etc.) or attenuate the blood glucose lowering effect (like steroids, thyroid hormones, etc.).

The safety of teneligliptin in pregnant women has not been established. Teneligliptin should be used in pregnant women or in women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.

It is unknown whether teneligliptin is excreted in human milk. But, animal studies (rat) have shown excretion of teneligliptin in milk. Thus, breast-feeding must be discontinued during administration of this product in lactating women.

No studies on the effects on the ability to drive and use machines have been performed. Patients who experience dizziness as an adverse reaction should avoid driving vehicles or using machines. Further, patients should be cautioned about the risk of hypoglycaemia especially when teneligliptin is co-administered with sulphonylurea and/or insulin.

The most common adverse reactions reported with teneligliptin are hypoglycemia and constipation. Other adverse reactions reported with the use of teneligliptin may include:

General: Fatigue, headache, dizziness, pyrexia.

Gastrointestinal Disorders: Intestinal obstruction, abdominal bloating, abdominal discomfort, nausea, vomiting, abdominal pain, flatulence, stomatitis, gastric polyps, colon polyps, duodenal ulcer, reflux esophagitis, diarrhea, loss of appetite, acute pancreatitis.

Liver: Increased AST (SGOT), increased ALT (SGPT), and increased γ-GTP

Kidney and Urinary System: Proteinuria, positive ketone bodies in urine.

Skin and Subcutaneous Tissue Disorders: Eczema, rash, itching, allergic dermatitis.

Respiratory System: Allergic rhinitis, nasopharyngitis, pneumonia.

Laboratory Investigations: Increase in serum levels of one or more of the followingamylase, lipase, CPK, potassium, uric acid.